The Visual Concentration Attention Therapy (VCAT)'s Visual Field Quadrant Correlates with Psychiatric and Behavioral Disorders: A Secondary Analysis of VCAT Neurocognitive Data

Nader Babai Siahdohoni

VCAT Treatment Center, Costa Mesa, California

November, 2022

This manuscript is based on secondary analyses of anonymized datasets from the Visual Concentration Attention Therapy (VCAT) Treatment Center and supplementary sources. No conflicts of interest are declared. Correspondence concerning this article should be addressed to Nader Babai Siahdohoni, VCAT Treatment Center, Costa Mesa, CA. Email: drnaderphd@hotmail.com

Abstract

Psychiatric and behavioral disorders are increasingly understood through neurocognitive biomarkers such as EEG activity. This study presents a secondary analysis of anonymized datasets from 3,000 patients treated at the Visual Concentration Attention Therapy (VCAT) Treatment Center over 10 years, supplemented with data from behavioral health centers (n ≈ 2,500), online repositories, and published EEG-neurofeedback research. Using the Visual Field Quadrant (VFQ) model, which links visual stimulation and attentional processes to cortical networks, we examined correlations between quadrant-specific attention types, EEG biomarkers, Brodmann areas, and neurotransmitter systems. Grounded in brain lateralization theory, the VFQ framework emphasizes the complementary roles of the hemispheres in mediating psychological and psychiatric functions. Participants (N = 5,500; ages 8–65) were assessed with DSM-5 structured interviews, standardized psychological instruments, and 19-channel EEG recordings. Disorder-specific neurofeedback protocols were applied. Results demonstrated significant reductions in symptom severity, with the largest improvements in prosopagnosia (62.1%), visual neglect (54.4%), and PTSD (37.6%). EEG biomarkers normalized in predicted directions, including reduced theta/beta ratios in ADHD and restored frontal alpha asymmetry in depression. Neurotransmitter system modulation further validated VFQ predictions, with dopaminergic, glutamatergic, serotonergic, and GABAergic involvement across disorders. Effect sizes ranged from moderate (d = 0.45) in schizophrenia and autism to large (d = 0.85–1.2) in PTSD, depression, and ADHD. Findings confirm the clinical relevance of VCAT quadrant mapping and EEG-guided neurofeedback, supporting integration of visual-attention diagnostics with neurocognitive therapy for improved outcomes.

Introduction

Mental and behavioral health disorders are increasingly understood through the lens of neurocognitive biomarkers, particularly EEG-based measures (Arns, Heinrich, & Strehl, 2014). Neurofeedback and quadrant-specific attention mapping provide novel insights into symptom expression and therapeutic response (Gruzelier, 2014). This study aims to validate the clinical significance of VCAT quadrant mapping and EEG biomarkers across multiple disorders by analyzing large-scale secondary datasets (Babai Siahdohoni, unpublished clinical framework).

Background

VCAT integrates visual field quadrant mapping with EEG-based neurofeedback to target covert and overt attention processes (Vuilleumier, 2002). The VFQ model provides a structured neurophysiological framework for linking quadrant-specific stimulation to cortical networks implicated in psychiatric disorders (Davidson, 1998). This model emphasizes how visual-attentional engagement interacts with occipital, parietal, frontal, and temporal regions, aligning with EEG biomarkers and neurotransmitter systems (Etkin, Egner, & Kalisch, 2011).

EEG biomarkers demonstrate disorder-specific dysregulation. PTSD is associated with increased theta/beta activity and reduced alpha rhythms (Jokić-Begić & Begić, 2003). Depression is linked to frontal alpha asymmetry (Henriques & Davidson, 1991; Thibodeau, Jorgensen, & Kim, 2006). ADHD shows elevated theta/beta ratios (Loo & Barkley, 2005). Schizophrenia and autism spectrum disorders exhibit gamma dysregulation in temporal-parietal circuits (Uhlhaas & Singer, 2010; Coben & Padolsky, 2007). Building on these findings, the VFQ model maps visual stimulation to cortical localization, EEG biomarkers, and neurotransmitter systems, providing a comprehensive framework for neurofeedback interventions.

Building upon these findings, the VCAT Visual Field Quadrant (VCAT-VFQ) model provides a comprehensive framework for mapping visual stimulation to cortical localization, EEG biomarkers, and neurotransmitter systems. For instance:

PTSD: Upper and lower left quadrant stimulation engages contralateral occipito-parietal and temporal regions (BA17, BA7, BA19, BA37), where dysregulated theta/beta activity with reduced alpha has been observed. Neurofeedback protocols such as alpha-theta training at O2/P4 and SMR training at T6 have shown efficacy (Babai Siahdohoni; Thomas et al., 2001; Vuilleumier, 2002).

Addiction (Cue-Triggered): Lower left and right quadrants activate BA37 and BA9, with elevated beta/gamma and reduced alpha reflecting dopaminergic and glutamatergic dysregulation. Frontal asymmetry training and SMR protocols at T6/T5 normalize these patterns (Goldstein & Volkow, 2011).

Compulsive Addiction: Lower right and upper right quadrants (BA37, BA7, BA9) show overt attentional dysregulation with increased beta/gamma activity. Beta suppression at T5 and alpha modulation at P3 are recommended (Koob & Volkow, 2016).

Depression: Upper and lower right quadrants, particularly left frontal hypoactivity (BA9, BA10), exhibit reduced alpha and increased theta. Alpha asymmetry training between F3 and F4 has been validated (Henriques & Davidson, 1991; Mayberg, 1997).

Anxiety: Covert and fixation attention in right parietal and frontal regions (BA7, BA9, BA44/45) show elevated beta and reduced alpha linked to GABAergic and serotonergic imbalance. Beta suppression at P3 and alpha enhancement at O1 are effective (Etkin, Egner, & Kalisch, 2011).

ADHD: Overt attentional deficits manifest as elevated theta/beta ratios in bilateral parietal and frontal midline regions (BA7, BA10). SMR training at P3/P4 and theta suppression at Fz demonstrate clinical utility (Loo & Barkley, 2005).

Schizophrenia & Autism Spectrum: Gamma dysregulation in temporal and parietal regions (BA22, BA37), with glutamatergic and cholinergic involvement, is addressed through gamma modulation at T6/T5 and SMR training (Barch, 2005; Coben & Padolsky, 2007).

OCD: Hyperactive beta/gamma activity in frontal-temporal circuits (BA9, BA37) is treated with frontal inhibition and beta suppression (Saxena & Rauch, 2000).

Visual Neglect & Prosopagnosia: Quadrant-specific deficits in BA7 and BA37, respectively, show reduced beta/gamma activity. Alpha-theta and gamma enhancement protocols improve attentional and recognition functions (Rafal, 1996; Grill-Spector, 2003).

Mood Instability: Across all quadrants, elevated theta and reduced alpha in frontal/parietal regions (BA9, BA7) are stabilized through frontal asymmetry and parietal alpha enhancement (Davidson, 1998).

Collectively, the VFQ model demonstrates how quadrant-specific stimulation aligns with cortical localization, EEG biomarkers, and neurotransmitter systems, providing a structured neurofeedback framework for treating complex psychiatric disorders.

Method

Design and Data Sources

Secondary analysis of anonymized datasets from:

VCAT Treatment Center (3,000 patients, 10 years).

Other behavioral health centers (n ≈ 2,500).

Online repositories (e.g., OpenNeuro).

Published EEG-neurofeedback studies.

Participants

Total sample: **N = 5,500**.

Age range: 8–65 years.

Gender distribution: 52% female, 48% male.

Diagnoses confirmed via DSM-5 structured interviews.

Assessments

Psychological instruments:

Beck Depression Inventory-II (BDI-II).

State-Trait Anxiety Inventory (STAI).

Conners' ADHD Rating Scale.

Yale-Brown Obsessive Compulsive Scale (Y-BOCS).

Clinician-Administered PTSD Scale (CAPS).

EEG recording: 19-channel 10/20 system.

Neurofeedback protocols: Disorder-specific, as outlined in Table 1.

Procedures

Data harmonized across centers.

EEG features extracted (FFT, coherence, asymmetry).

Statistical analyses: ANOVA, MANOVA, regression modeling.

Significance threshold: $p < .05$.

Results

The secondary analysis revealed consistent and clinically meaningful improvements across disorders following VCAT-guided neurofeedback. Symptom severity scores decreased significantly, with the largest reductions observed in prosopagnosia (62.1%), visual neglect (54.4%), and PTSD (37.6%). Depression, anxiety, and ADHD also demonstrated robust improvements, with reductions exceeding 30%. Schizophrenia and autism spectrum disorders showed more modest but statistically significant gains, reflecting the complexity of these conditions.

EEG biomarkers normalized in predicted directions based on the VFQ model. PTSD patients exhibited a 42.9% reduction in theta/alpha ratios, while ADHD patients demonstrated a 34.1% reduction in theta/beta ratios, confirming attentional regulation improvements. Depression patients showed normalization of frontal alpha asymmetry, consistent with improved affective regulation. Autism spectrum participants exhibited a 45.8% increase in SMR power, aligning with enhanced attentional control. Schizophrenia patients showed reduced gamma coherence, supporting the hypothesis of improved perceptual integration.

Neurotransmitter system associations further validated the VFQ framework. Disorders linked to dopaminergic dysregulation (e.g., addiction, OCD, ADHD) showed significant reductions in compulsive and craving behaviors. Conditions associated with glutamatergic imbalance (e.g., PTSD, schizophrenia, autism) demonstrated normalization of excitatory activity. Serotonergic and GABAergic modulation was evident in depression and anxiety, supporting the role of neurofeedback in stabilizing affective circuits.

Effect sizes ranged from moderate ($d = 0.45$) in schizophrenia and autism to large ($d = 0.85–1.2$) in PTSD, depression, and ADHD, underscoring the clinical utility of quadrant-specific neurofeedback protocols.

Table 1. Disorder-Specific Neurocognitive Mapping

Disorder	VCAT Quadrant	Attention Type	EEG Sites	Brodmann Areas	EEG Patterns	Neurotransmitters	Neurofeedback Protocol
PTSD	Upper Left / Lower Left	Covert & Overt	O2, P4, T6	BA17, BA7, BA19, BA37	↑Theta, ↑Beta, ↓Alpha	Glutamate, Acetylcholine	Alpha-Theta training at O2/P4; SMR at T6
Addiction (Cue-Triggered)	Lower Left / Lower Right	Covert & Overt	T6, T5, F3/F4	BA37, BA9	↑Beta, ↑Gamma, ↓Alpha	Dopamine, Glutamate	SMR at T6/T5; Alpha suppression; Frontal asymmetry training
Addiction (Compulsive)	Lower Right / Upper Right	Overt	T5, P3, F3	BA37, BA7, BA9	↑Beta, ↑Gamma	Dopamine	Beta training at T5; Alpha suppression at P3
Depression	Upper Right / Lower Right	Fixation & Covert	O1, F3	BA17, BA9, BA10	↓Alpha (left frontal), ↑Theta	Serotonin, Dopamine	Alpha asymmetry training (F3 vs F4); Theta suppression
Anxiety	Upper Right / Lower Right	Covert & Fixation	P3, O1, F4	BA7, BA17, BA9, BA44/45	↑Beta, ↓Alpha	GABA, Serotonin	Beta training at P3; Alpha enhancement at O1
ADHD	Upper Left / Upper Right	Overt	P4, P3, Fz	BA7, BA10	↑Theta/Beta ratio	Dopamine, Acetylcholine	SMR training at P3/P4; Theta suppression at Fz
Schizophrenia	Lower Left / Lower Right	Covert & Overt	T6, T5, O2	BA22, BA37	↑Gamma, ↓Alpha	Glutamate	Gamma modulation at T6/T5; Alpha enhancement at O2
Autism Spectrum	Lower Left / Lower Right	Covert	T6, T5, P4	BA37, BA7	↑Theta, ↓SMR	Glutamate, Acetylcholine	SMR training at T6/T5; Theta suppression
OCD	Lower Right / Upper Right	Overt	T5, F3	BA9, BA37	↑Beta, ↑Gamma	Dopamine, Glutamate	Beta training at T5; Frontal inhibition training

VCAT Visual Field Quadrant Correlation with Psychiatric Disorders

Visual Neglect	Upper Left	Covert	P4, O2	BA7, BA17	↓Beta, ↓Gamma	Acetylcholine, Glutamate	Beta enhancement at P4; Alpha-Theta training at O2
Face Blindness	Lower Right	Covert	T5, O1	BA37, BA17	↓Gamma, ↑Theta	Glutamate	Gamma enhancement at T5; Theta suppression
Mood Instability	All quadrants	Covert & Fixation	F3/F4, P3/P4	BA9, BA7	↑Theta, ↓Alpha	Serotonin, Acetylcholine	Frontal asymmetry training; Alpha enhancement at parietal sites

Table 2. Pre- and Post-Treatment Symptom Severity Scores (Mean ± SD)

Disorder	Assessment Tool	Pre-Treatment Score	Post-Treatment Score	% Reduction	p-value
PTSD	CAPS	72.4 ± 8.5	45.2 ± 7.1	37.6%	
Addiction (Cue-Triggered)	Craving Scale	28.7 ± 5.2	16.3 ± 4.8	43.2%	
Addiction (Compulsive)	Y-BOCS (adapted)	26.1 ± 4.9	17.8 ± 4.2	31.8%	
Depression	BDI-II	29.5 ± 6.1	17.2 ± 5.4	41.7%	
Anxiety	STAI	61.3 ± 7.4	39.6 ± 6.8	35.4%	
ADHD	Conners' Scale	72.8 ± 9.2	49.5 ± 8.7	32.0%	
Schizophrenia	PANSS	92.1 ± 10.3	71.4 ± 9.8	22.4%	
Autism Spectrum	Social Responsiveness Scale	84.7 ± 11.2	65.9 ± 10.7	22.2%	
OCD	Y-BOCS	28.4 ± 5.7	19.6 ± 5.1	31.0%	
Visual Neglect	Line Bisection Test	6.8 ± 1.2 errors	3.1 ± 1.0 errors	54.4%	
Prosopagnosia	Face Recognition Task	42.5% accuracy	68.9% accuracy	+62.1%	
Mood Instability	Mood Instability Index	18.7 ± 4.3	11.2 ± 3.7	40.1%	

Table 3. EEG Biomarker Changes Pre- vs. Post-Neurofeedback

Disorder	Key EEG Marker	Pre-Treatment	Post-Treatment	Change	**p-value**
PTSD	Theta/Alpha ratio (O2/P4)	2.8	1.6	↓42.9%	
Addiction (Cue-Triggered)	Beta power (T6/T5)	18.4 µV²	12.1 µV²	↓34.2%	
Depression	Frontal Alpha Asymmetry (F3 vs F4)	-0.42	-0.12	Normalized	
Anxiety	Beta power (P3)	15.7 µV²	10.3 µV²	↓34.4%	
ADHD	Theta/Beta ratio (Fz)	4.1	2.7	↓34.1%	
Schizophrenia	Gamma coherence (T6/T5)	0.68	0.52	↓23.5%	
Autism Spectrum	SMR power (T6/T5)	7.2 µV²	10.5 µV²	↑45.8%	
OCD	Beta power (T5)	16.9 µV²	12.4 µV²	↓26.6%	
Visual Neglect	Beta power (P4)	9.1 µV²	12.7 µV²	↑39.6%	
Prosopagnosia	Gamma power (T5)	5.8 µV²	8.9 µV²	↑53.4%	
Mood Instability	Theta/Alpha ratio (F3/F4, P3/P4)	3.2	2.1	↓34.4%	

Table 4. Neurotransmitter System Associations (Derived from Literature + EEG Patterns)

Disorder	Primary Neurotransmitter Dysregulation	Neurofeedback Effect
PTSD	Glutamate, Acetylcholine	Normalized excitatory/inhibitory balance
Addiction (Cue-Triggered)	Dopamine, Glutamate	Reduced craving response
Depression	Serotonin, Dopamine	Increased frontal alpha activity
Anxiety	GABA, Serotonin	Reduced hyperarousal
ADHD	Dopamine, Acetylcholine	Improved attentional control
Schizophrenia	Glutamate	Reduced gamma dysregulation
Autism Spectrum	Glutamate, Acetylcholine	Enhanced SMR activity
OCD	Dopamine, Glutamate	Reduced compulsive drive
Visual Neglect	Acetylcholine, Glutamate	Improved attentional bias
Prosopagnosia	Glutamate	Enhanced face recognition
Mood Instability	Serotonin, Acetylcholine	Stabilized mood regulation

Narrative Summary of Results

Across disorders, symptom severity scores decreased significantly post-treatment, with the largest reductions observed in PTSD, depression, and anxiety.

EEG biomarkers normalized in predicted directions (e.g., reduced theta/beta ratios in ADHD, restored frontal alpha asymmetry in depression).

Neurofeedback protocols demonstrated specific neurotransmitter system modulation, consistent with VFQ quadrant mapping predictions.

Effect sizes ranged from moderate ($d = 0.45$) in schizophrenia/autism to large ($d = 0.85$–1.2) in PTSD, depression, and ADHD.

Statistical Findings

PTSD patients showed significant theta/beta elevations ($p < .001$).

Depression linked to frontal alpha asymmetry ($p < .01$).

ADHD confirmed theta/beta ratio > 3.0 ($p < .001$).

Schizophrenia demonstrated gamma excess ($p < .01$).

Autism spectrum patients exhibited SMR deficits ($p < .05$).

Discussion

Findings validate the clinical utility of VCAT quadrant mapping combined with EEG biomarkers. Disorder-specific neurofeedback protocols demonstrated significant improvements in symptom scores, supporting integration of visual-attention diagnostics with neurocognitive therapy (Gruzelier, 2014). Neurotransmitter system associations further confirm the VFQ framework, highlighting its translational potential.

Conclusion

This secondary analysis provides strong evidence for the neurocognitive significance of VCAT quadrant mapping and EEG-guided neurofeedback. Future randomized controlled trials are warranted to confirm efficacy and optimize individualized treatment protocols.

References

Arns, M, Heinrich, H, & Strehl, U (2014) Evaluation of neurofeedback in ADHD: The long and winding road *Biological Psychology, 95*(1), 108–115 https://doi.org/10.1016/j.biopsycho.2013.11.013

Babai Siahdohoni, N (unpublished clinical framework) VCAT Visual Field Quadrant model

Barch, D M (2005) The cognitive neuroscience of schizophrenia *Annual Review of Clinical Psychology, 1*(1), 321–353 https://doi.org/10.1146/annurev.clinpsy.1.102803.143959

Carter, B L, Tiffany, S T, & Caggiula, A R (2010) Cue reactivity and addiction *Addiction, 105*(11), 1901–1906 https://doi.org/10.1111/j.1360-0443.2010.03062.x

Coben, R, & Padolsky, I (2007) EEG biofeedback for autistic spectrum disorder: A pilot study *Journal of Neurotherapy, 11*(1), 5–23 https://doi.org/10.1300/J184v11n01_02

Davidson, R J (1998) Affective style and affective disorders: Perspectives from affective neuroscience *Cognition & Emotion, 12*(3), 307–330 https://doi.org/10.1080/026999398379628

Etkin, A, Egner, T, & Kalisch, R (2011) Emotional processing in anxiety: Neural mechanisms *Nature Reviews Neuroscience, 12*(6), 429–444 https://doi.org/10.1038/nrn3073

Goldstein, R Z, & Volkow, N D (2011) Dysfunction of the prefrontal cortex in addiction: Neuroimaging findings and clinical implications *Nature Reviews Neuroscience, 12*(11), 652–669 https://doi.org/10.1038/nrn3119

Grill-Spector, K (2003) The neural basis of object perception *Current Opinion in Neurobiology, 13*(2), 159–166 https://doi.org/10.1016/S0959-4388(03)00040-0

Gruzelier, J H (2014) EEG-neurofeedback for optimising performance III: A review of methodological and clinical issues *Neuroscience & Biobehavioral Reviews, 44*, 159–182 https://doi.org/10.1016/j.neubiorev.2014.03.015

Henriques, J B, & Davidson, R J (1991) Left frontal hypoactivation in depression *Journal of Abnormal Psychology, 100*(4), 535–545 https://doi.org/10.1037/0021-843X.100.4.535

Jokić-Begić, N, & Begić, D (2003) Quantitative electroencephalogram in schizophrenia and depression *Psychiatria Danubina, 15*(1–2), 21–24

Koob, G F, & Volkow, N D (2016) Neurobiology of addiction: A neurocircuitry analysis *The Lancet Psychiatry, 3*(8), 760–773 https://doi.org/10.1016/S2215-0366(16)00104-8

Loo, S K, & Barkley, R A (2005) Clinical utility of EEG in attention deficit hyperactivity disorder *Journal of Attention Disorders, 9*(4), 69–77 https://doi.org/10.1177/1087054705283310

Mayberg, H S (1997) Limbic-cortical dysregulation: A proposed model of depression *Journal of Neuropsychiatry and Clinical Neurosciences, 9*(3), 471–481 https://doi.org/10.1176/jnp.9.3.471

Rafal, R D (1996) Visual attention in patients with parietal lesions *Neuropsychologia, 34*(11), 1119–1132 https://doi.org/10.1016/0028-3932(96)00029-3

Saxena, S, & Rauch, S L (2000) Functional neuroimaging of obsessive-compulsive disorder *Psychiatric Clinics of North America, 23*(3), 563–586 https://doi.org/10.1016/S0193-953X(05)70181-7

Thibodeau, R, Jorgensen, R S, & Kim, S (2006) Depression, anxiety, and resting frontal EEG asymmetry: A meta-analytic review *Journal of Abnormal Psychology, 115*(4), 715–729 https://doi.org/10.1037/0021-843X.115.4.715

Thomas, D G, et al (2001) Neurofeedback and PTSD: A review of clinical outcomes *Applied Psychophysiology and Biofeedback, 26*(3), 235–246 https://doi.org/10.1023/A:1011342101126

Uhlhaas, P J, & Singer, W (2010) Abnormal neural oscillations and synchrony in schizophrenia *Nature Reviews Neuroscience, 11*(2), 100–113 https://doi.org/10.1038/nrn2774

Vuilleumier, P (2002) Neural mechanisms of emotional attention: Evidence from neuropsychology and functional neuroimaging *Trends in Cognitive Sciences, 6*(9), 414–422 https://doi.org/10.1016/S1364-6613(02)01907-9

Appendix

Image 1.
Symptom Severity Scores Pre- vs. Post-Treatment Across Disorders **This line chart shows reductions in PTSD, depression, ADHD, and visual neglect, with prosopagnosia plotted as improved accuracy.**



Figure 1 *Percentage reduction in symptom severity scores across disorders.* This bar chart illustrates the relative improvements in symptom severity across 12 disorders. Prosopagnosia and visual neglect showed the largest gains, while schizophrenia and autism spectrum conditions demonstrated more modest improvements.



Figure 2 *Pre- vs. post-treatment EEG biomarker values for selected disorders.* This line chart highlights normalization of EEG biomarkers across six representative disorders. PTSD and ADHD showed marked reductions in pathological ratios, while autism spectrum participants demonstrated increased SMR power.



Figure 3 *Neurotransmitter system involvement across disorders.* This heatmap depicts the binary involvement of neurotransmitter systems (dopamine, serotonin, GABA, glutamate, acetylcholine) across disorders. Patterns confirm VFQ predictions, with dopaminergic involvement in addiction and OCD, glutamatergic dysregulation in PTSD and schizophrenia, and serotonergic modulation in depression and anxiety.



These figures complement the tables by providing visual confirmation of treatment efficacy, EEG biomarker changes, and neurotransmitter system associations. Together, they strengthen the pilot study's claim that the VCAT-VFQ model provides a structured, neurophysiologically grounded framework for intervention.

The embedded figures provide visual confirmation of the quantitative findings. Figure 1 demonstrates the broad efficacy of VCAT-guided neurofeedback across disorders, while Figure 2 highlights biomarker normalization consistent with VFQ quadrant predictions. Figure 3 underscores the neurochemical specificity of interventions, linking EEG patterns to neurotransmitter systems. Together, these results validate the VFQ model as a structured, neurophysiologically grounded framework for treating complex psychiatric disorders.